Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its HepTcell immunotherapeuticfor the treatment of chronic hepatitis B infection will be presented at the 2017 Keystone Symposia Conference taking place October 25 – 29, 2016 in London.